Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Research Impact

Home
Menu

A risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy patients

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø research to develop a risk model to predict the chances of sudden cardiac death in people with HCM is helping clinicians and patients worldwide make better decisions about life-saving treatments.

Cardiomyopathy

12 April 2022

Hypertrophic cardiomyopathy (HCM) is an inherited heart disease that affects approximately 36 million people worldwide. Many individuals with the condition are at high risk of dying when their heart stops suddenly and require surgery to insert an implantable cardioverter defibrillator (ICD).Ìý

The invasive ICD therapy significantly reduces sudden cardiac death (SCD) events and can return life expectancy to near normal. However, in 1 in 10 cases complications occur and for some HCM patients the risks of this invasive procedure may outweigh the benefits.ÌýÌý

A research team led by Professor Rumana Omar (Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Department of Statistical Science)Ìýin collaboration with Professor Perry Elliott (Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Institute of Cardiovascular Science)Ìýused statistical models to develop and evaluate a risk prediction model to identify which patients were at highest risk of SCD.Ìý

The risk prediction tool accurately assesses individual’s risk of SCD in people with HCM, so those at high risk can be offered a life-saving ICD implant and minimise ICD implantation in patients with low risk of SCD.Ìý

To develop the tool, an international cohort of 3,675 HCM patients from six European centres was established, through the HCM-RISK Consortium collaboration, which includes clinicians and health researchers from Europe, North America, Israel, and the Far East.ÌýÌý

The HCM Risk-SCD tool classifies patients into low, moderate, or severe risk groups based on their predicted probabilities of a SCD event. The algorithm has been incorporated into the European Society of Cardiology (ESG) guidelines, endorsed in 57 countries. It is currently used by cardiologists in at least 25 countries to risk-stratify HCM patients during their clinical assessment and decide on the best treatment option.ÌýÌý

To assess the model’s performance in clinical settings, it was tested on 3,703 patients from a geographically diverse cohort recruited from 14 centres across the US, Europe, the Middle East, and Asia. The tool was also independently validated in a wider patient group including HCM patients treated with a non-surgical procedure to treat obstruction.ÌýÌý

The is freely available online and can be downloaded as an App.ÌýÌý

In a survey carried out by ESC, more than 695 cardiologists across 25 countries provided detail on how they use the risk tool in clinical practice. Three quarters of the respondents reported using the tool one to fiveÌýtimes in a six-month period and eight out of ten said the tool has improved their clinical decision making.

An optimal management of ICD implantations in HCM patients balancing with their SCD risks can be achieved using this tool, potentially resulting in cost saving for the NHS.ÌýÌý

Research synopsis

A risk prediction model for sudden cardiac death in hypertrophicÌýcardiomyopathy patients (HCM Risk-SCD)Ìý

One in 500 people are at risk of sudden cardiac death (SCD) due to an inherited heart muscle disorder, hypertrophic cardiomyopathy (HCM). Research at Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø to develop a risk model to predict the chances ofÌýsudden cardiac death in people with HCM is helping clinicians and patients worldwide make better decisions about life-saving treatments.Ìý

Links

Photo creditÌý

  • iStock, credit: